Publications

Journal Article
Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review
Ppublish 2690 citations
Electronic publication date
July 27, 2011

View on Pubmed.gov 21562580 | View on doi.org 10.1038/nrc3066

Cell-free nucleic acids as biomarkers in cancer patients.

Search for publications in this journal Nat Rev Cancer - 11(6):426-37

Abstract

DNA, mRNA and microRNA are released and circulate in the blood of cancer patients. Changes in the levels of circulating nucleic acids have been associated with tumour burden and malignant progression. In the past decade a wealth of information indicating the potential use of circulating nucleic acids for cancer screening, prognosis and monitoring of the efficacy of anticancer therapies has emerged. In this Review, we discuss these findings with a specific focus on the clinical utility of cell-free nucleic acids as blood biomarkers.

References

Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):67-71

Trends Mol Med. 2010 Sep;16(9):398-406

Br J Cancer. 2009 Nov 17;101(10):1724-30

Liver Int. 2008 Mar;28(3):393-401

Cited by 2690 citations (total)

Journal Article

Circulating cell-free human telomerase reverse transcriptase mRNA in plasma and its potential diagnostic and prognostic value for gastric cancer.

Electronic publication date February 14, 2014

Search for publications in this journal Int J Clin Oncol

Yi Kang [...] Jia Shang et al.

BACKGROUND

Our aims were to detect circulating cell-free human telomerase reverse transcriptase (hTERT) mRNA in the plasma of gastric cancer patients...

Comparative Study Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Comparing the MicroRNA spectrum between serum and plasma.

Electronic publication date April 12, 2013

Search for publications in this journal PLoS One

Kai Wang [...] David J Galas et al.

MicroRNAs (miRNAs) are small, non-coding RNAs that regulate various biological processes, primarily through interaction with messenger RNAs. The levels of...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances